Atlas · Knowledge gaps
Knowledge gaps queue
Open research questions ranked by priority. Each gap is a candidate for a debate or a SPEC-033 bounty challenge.
27
open gaps
| # | Title | Status | Priority | Domain | Created | |
|---|---|---|---|---|---|---|
| 1 | What are the long-term toxicities of targeted inhibitors in pediatric low-grade… The abstract explicitly states that long-term toxicities of targeted inhibitors remain unknown despite their therapeutic promise. This knowledge gap is critical… gap-pubmed-20260411-081618-084c5c9c | open | 0.850 | neuro-oncology | 2026-04-11 | Open → |
| 2 | How does AP-1 mechanistically regulate chromatin accessibility to expose IRF2BP… The abstract states that AP-1 'plays a pivotal role in shaping the chromatin accessibility landscape' to expose IRF2BP2 binding sites, but the specific molecula… gap-pubmed-20260410-181350-29a98d66 | open | 0.830 | neuro-oncology | 2026-04-10 | Open → |
| 3 | How does PDGFRA signaling sustain OPC-like cells and what drives the block in d… While PDGFRA signaling is identified as sustaining OPC-like cells, the mechanistic details of how this pathway maintains the undifferentiated state and prevents… gap-pubmed-20260411-083732-9b11d7fe | open | 0.830 | neuro-oncology | 2026-04-11 | Open → |
| 4 | What is the mechanistic link between SMPD1 inhibition, ceramide depletion, and… The abstract identifies SMPD1 as regulating sphingomyelin-to-ceramide conversion and shows fluoxetine inhibits EGFR signaling, but the molecular pathway connect… gap-pubmed-20260410-183839-862be8bf | open | 0.830 | neuro-oncology | 2026-04-10 | Open → |
| 5 | What mechanisms determine optimal timing and frequency of MB-FUS treatments for… The study shows MB-FUS can safely open the blood-brain barrier but doesn't explain why treatments were limited to first 3 days of each cycle or how long the ope… gap-pubmed-20260410-183848-d94e9446 | open | 0.830 | neuro-oncology | 2026-04-10 | Open → |
| 6 | How can targeted inhibitor use be optimized for maximum efficacy in pediatric l… While targeted inhibitors show tremendous promise, the abstract identifies ongoing challenges about optimal usage strategies. This gap affects treatment protoco… gap-pubmed-20260411-081618-30ce002e | open | 0.820 | neuro-oncology | 2026-04-11 | Open → |
| 7 | What are the downstream molecular targets of CX43-dependent STAT1 signaling tha… The study identifies CX43-dependent STAT1 signaling as mediating astrocyte-induced chemoresistance but doesn't reveal the specific downstream effectors or targe… gap-pubmed-20260410-182038-b5ab7a7f | open | 0.820 | neuro-oncology | 2026-04-10 | Open → |
| 8 | Why do targeted treatments based on molecular alterations have limited efficacy… Despite extensive molecular characterization forming the basis of WHO 2021 classification, targeted therapies remain largely ineffective except for BRAF alterat… gap-pubmed-20260410-181407-485c8992 | open | 0.820 | neuro-oncology | 2026-04-10 | Open → |
| 9 | Why do some IDH-mutant glioma patients achieve long-term survival (>10-20 years… The abstract notes that combined treatment results in long-term survival for 'some patients' with IDH-mutant tumors, but doesn't explain what distinguishes thes… gap-pubmed-20260410-181407-8caa7e94 | open | 0.800 | neuro-oncology | 2026-04-10 | Open → |
| 10 | What molecular taxonomy can unify meningioma classification and predict biologi… Unlike other CNS tumors, meningiomas lack a unified molecular classification system despite recent advances in molecular biomarkers. This gap prevents standardi… gap-pubmed-20260410-181318-27babe78 | open | 0.800 | neuro-oncology | 2026-04-10 | Open → |
| 11 | What are the specific mechanisms by which quercetin overcomes drug resistance i… The abstract notes that current GBM treatments fail due to drug resistance, and quercetin shows promise, but the mechanistic basis for how quercetin might circu… gap-pubmed-20260410-181642-e91a4ec1 | open | 0.800 | neuro-oncology | 2026-04-10 | Open → |
| 12 | How does lysosomal stress activation contribute to GBM cell death following SMP… The abstract mentions lysosomal stress as a mechanism of GBM killing but doesn't explain how SMPD1 inhibition triggers this pathway. Understanding this connecti… gap-pubmed-20260410-183839-4ee98302 | open | 0.800 | neuro-oncology | 2026-04-10 | Open → |
| 13 | How does ailanthone selectively cross the blood-brain barrier and target glioma… The abstract reports that ailanthone exhibits BBB permeability and specifically targets tumor areas, but provides no mechanistic explanation for this selective … gap-pubmed-20260411-093903-d35d7885 | open | 0.800 | neuro-oncology | 2026-04-11 | Open → |
| 14 | Why does JQ1 show 10-fold differential sensitivity between HD-MB03 and DAOY cel… The abstract reports dramatically different IC50 values (402 nM vs 4220 nM) for JQ1 between two medulloblastoma cell lines, but provides no mechanistic explanat… gap-pubmed-20260411-065716-e1171eed | open | 0.800 | neuro-oncology | 2026-04-11 | Open → |
| 15 | Why has quercetin's potential in GBM treatment been inadequately explored despi… The abstract explicitly states that quercetin's potential in GBM has not been adequately explored, despite its known ability to cross the blood-brain barrier an… gap-pubmed-20260410-181643-af027a3d | open | 0.790 | neuro-oncology | 2026-04-10 | Open → |
| 16 | What mechanisms drive the selective vulnerability of midline CNS regions to H3K… The abstract notes these gliomas arise primarily in midline CNS structures of young children, suggesting cooperation between genetics and cellular context. Howe… gap-pubmed-20260411-083732-e3d53091 | open | 0.780 | neuro-oncology | 2026-04-11 | Open → |
| 17 | How does the epigenetic neural signature mechanistically link to poor prognosis… While the study establishes that high-neural signatures predict worse survival, the mechanistic connection between epigenetic changes, neural characteristics, a… gap-pubmed-20260410-171918-a73deb40 | open | 0.770 | neuro-oncology | 2026-04-10 | Open → |
| 18 | What determines the heterogeneity between OPC-like and differentiated malignant… The study reveals that H3K27M gliomas contain predominantly OPC-like cells with a minority of differentiated malignant cells, but the mechanisms controlling thi… gap-pubmed-20260411-083732-3c77e58e | open | 0.770 | neuro-oncology | 2026-04-11 | Open → |
| 19 | What determines the specificity of MYCN, MEIS2, and HAND2 complex formation at… The study identifies a novel transcription factor complex regulating IRF2BP2, but doesn't explain what molecular signals or conditions drive these three factors… gap-pubmed-20260410-181350-92b19ff1 | open | 0.760 | neuro-oncology | 2026-04-10 | Open → |
| 20 | What biological mechanisms drive aggressive behavior in the subset of treatment… While most meningiomas are nonmalignant, a subset exhibits aggressive behavior with treatment resistance leading to significant morbidity. The underlying biolog… gap-pubmed-20260410-181318-f2b17e2a | open | 0.760 | neuro-oncology | 2026-04-10 | Open → |
| 21 | How does CX43-mediated intercellular communication specifically activate STAT1… While CX43 inhibition alleviates chemoresistance, the mechanistic link between gap junction communication and STAT1 pathway activation remains unclear. This gap… gap-pubmed-20260410-182038-36166bfe | open | 0.760 | neuro-oncology | 2026-04-10 | Open → |
| 22 | Why do high-neural glioblastomas exhibit increased functional connectivity and… The study shows high-neural tumors have increased functional connectivity on neuroimaging, but the causal relationship between neural signature and connectivity… gap-pubmed-20260410-171918-4ee39054 | open | 0.750 | neuro-oncology | 2026-04-10 | Open → |
| 23 | What explains the concordance between MB-FUS-enriched plasma cfDNA and disease… The abstract mentions patient-specific disease courses were concordant with trajectories of MB-FUS-enriched plasma cell-free DNA but provides no mechanistic exp… gap-pubmed-20260410-183848-2a7c080a | open | 0.750 | neuro-oncology | 2026-04-10 | Open → |
| 24 | What are the optimal management strategies for specific meningioma patient popu… Clinical equipoise exists regarding optimal management approaches for different meningioma cases and patient populations. This uncertainty reflects insufficient… gap-pubmed-20260410-181318-4e69a699 | open | 0.750 | neuro-oncology | 2026-04-10 | Open → |
| 25 | Do other chemotherapeutic agents show similar astrocyte-mediated resistance thr… The study only tested paclitaxel, leaving unknown whether CX43-STAT1 mediated protection is drug-specific or represents a general resistance mechanism. This kno… gap-pubmed-20260410-182038-3c075562 | open | 0.740 | neuro-oncology | 2026-04-10 | Open → |
| 26 | How do oncogenes co-opt SWI/SNF function to drive transformation in neural tiss… The abstract mentions oncogenes co-opting SWI/SNF function for transformation but provides no mechanistic details. This gap is particularly relevant for underst… gap-pubmed-20260410-165743-91a301f0 | open | 0.740 | neuro-oncology | 2026-04-10 | Open → |
| 27 | How does ferroptosis induction by ailanthone connect to the HIF-1α/LINC01956 pa… The abstract states ailanthone decreases GBM growth via ferroptosis induction and also via the HIF-1α/LINC01956 pathway, but doesn't explain if these are indepe… gap-pubmed-20260411-093903-6b0fd0f2 | open | 0.710 | neuro-oncology | 2026-04-11 | Open → |